4A3 Stock Overview
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immatics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.25 |
| 52 Week High | US$13.48 |
| 52 Week Low | US$6.57 |
| Beta | 0.68 |
| 1 Month Change | -7.36% |
| 3 Month Change | -14.71% |
| 1 Year Change | 54.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4A3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | 1.8% | 1.1% |
| 1Y | 54.1% | -23.5% | 1.9% |
Return vs Industry: 4A3 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 4A3 exceeded the German Market which returned 2% over the past year.
Price Volatility
| 4A3 volatility | |
|---|---|
| 4A3 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4A3's share price has been volatile over the past 3 months.
Volatility Over Time: 4A3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 484 | Harpreet Singh | www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
Immatics N.V. Fundamentals Summary
| 4A3 fundamental statistics | |
|---|---|
| Market cap | €961.50m |
| Earnings (TTM) | -€96.99m |
| Revenue (TTM) | €54.00m |
17.8x
P/S Ratio-9.9x
P/E RatioIs 4A3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4A3 income statement (TTM) | |
|---|---|
| Revenue | €54.00m |
| Cost of Revenue | €118.66m |
| Gross Profit | -€64.67m |
| Other Expenses | €32.33m |
| Earnings | -€96.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -119.76% |
| Net Profit Margin | -179.63% |
| Debt/Equity Ratio | 0% |
How did 4A3 perform over the long term?
See historical performance and comparison